Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT05060588
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT05060588
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05060588. Randomized; triple masking; primary purpose treatment. Start 2021-10 (anticipated); primary completion 2022-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction
- Condition
- Myocardial Infarction
- Condition
- Hypertension
- Intervention (Drug)
- Sacubitril/Valsartan 49/51mg/Tab
- Intervention (Drug)
- Valsartan 80mg/Tab
- Lead sponsor
- Qingdao Central Hospital
Record details
- Record id
cardio:ct-nct05060588- Content hash
e0591874990c20d7984c50f1ca33e9115eccc1b53c743efa2d56587c087f99c0